Marina Biotech (MRNA)
Marina Biotech Revenues: 0.286M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
MRNA Revenues Rankings
| Overall | 1st percentile | 4371 of 4432 |
| Sector | 6th percentile | 441 of 470 in Healthcare |
| Industry | 12th percentile | 116 of 132 in Biotechnology |
MRNA Revenues Range, Past 5 Years
| Minimum | 0.064M | Sep 2009 |
| Maximum | 14.15M | Mar 2009 |
| Average | 1.865M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these MRNA related companies
MRNA News
URGENT: $MRNA filed to delay releasing annual earnings results (SEC Filing Form NT 10K) http://stks.co/3BnE
about 58 days ago by MarketBrief
about 58 days ago by MarketBrief
Marina Biotech (MRNA), ProNA Enter DNAi-Based Therapeutic Licensing Agreement
Mar 14, 7:21AM Street Insider
Mar 14, 7:21AM Street Insider
$RXII $GALE $MRNA $ALNY $CYTR $ARWR RIP140 regulation of diabetes Patent8093223 Czech(RXi Pharmaceuticals) http://stks.co/1tyQ
about 139 days ago by biotech
about 139 days ago by biotech
$MRNA convergence on MACD. Possible stochastic crossover forming on 5 day chart.
about 170 days ago by pasleyt
about 170 days ago by pasleyt
$ALNY rodman comments: these
results represent a key milestone in the advancement of RNAi as a new
class of therapeutis $MRNA $GALE
about 191 days ago by biotech
about 191 days ago by biotech
$MRNA The long wait is finally over: Systemic RNAi delivery has been proven in Man http://stks.co/1DI9 $GALE $RXII $ALNY
about 191 days ago by biotech
about 191 days ago by biotech
$MRNA other than the two spikes, volume dried up. Needs more liquidity to gain momentum like $PEIX
about 194 days ago by net2dave
about 194 days ago by net2dave
$ALNY $MRNA $GALE http://stks.co/15Ih gene mutation that drops heart-attack risk by as much as 88 %
about 201 days ago by biotech
about 201 days ago by biotech
$MRNA http://stks.co/159A President and CEO of Marina Biotech, Inc. "This drug discovery engine allows us to capitalize..."
about 201 days ago by stockbullish
about 201 days ago by stockbullish
$MRNA believe we are 1 of the strongest potential partners for pharma companies...expect..to establish 1 or more partnerships in coming year
about 202 days ago by biotech
about 202 days ago by biotech
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| MRNA | 0.7389 | +0.02 | +2.58% | 5.842M |
| MRLN | 13.98 | -0.39 | -2.71% | 182.64M |
| MRK | 37.41 | -0.18 | -0.48% | 114.42B |
| MRH | 20.44 | -0.10 | -0.49% | 1.219B |
| MRGE | 2.40 | -0.08 | -3.23% | 225.70M |
| MRF | 7.84 | -0.06 | -0.76% | |
| MNDO | 1.68 | -0.03 | -1.75% | 32.03M |
| MMYT | 13.61 | -0.64 | -4.49% | 525.11M |
| MMV | 15.00 | +0.00 | +0.03% | |
| MMT | 6.91 | -0.07 | -1.00% |
